Hebrew University drug trials show 50 percent cure rate in lab mice
Acute myeloid leukemia is one of the most aggressive cancers. While other cancers have benefitted from new treatments, there has been no encouraging news for most leukemia patients for the past 40 years. Until now.
As published today in the scientific journal Cell, Professor Yinon Ben-Neriah and his research team at the Hebrew University of Jerusalem (HU)’s Faculty of Medicine have developed a new biological drug with a cure rate of 50% for lab mice with acute leukemia.
Leukemia produce a variety (and a high quantity) of proteins that together provide leukemic cells with rapid growth and death protection from chemotherapy.
To date, most of the biological cancer drugs used to treat leukemia target only individual leukemic cell proteins. However, during “targeted therapy” treatments, leukemic cells quickly activate their other proteins to block the drug. The result is drug-resistant leukemic cells which quickly regrow and renew the disease.
However, the new drug developed by Ben-Neriah and his team functions like a cluster bomb. It attacks several leukemic proteins at once, making it difficult for the leukemia cells to activate other proteins that can evade the therapy. Further, this single molecule drug accomplishes the work of three or four separate drugs, reducing cancer patients need to be exposed to several therapies and to deal with their often unbearable side-effects.
Additionally promising, is the new drug’s ability to eradicate leukemia stem cells. This has long been the big challenge in cancer therapy and one of the main reasons that scientists have been unable to cure acute leukemia.
“We were thrilled to see such a dramatic change even after only a single dose of the new drug. Nearly all of the lab mice’s’ leukemia signs disappeared overnight,” shared professor Ben-Neriah.
BioTheryX recently bought the rights to this promising drug from HU’s technology transfer company Yissum. Together with Ben-Neriah’s research team, they are now applying for FDA approval for phase I clinical studies.
The Latest on: Acute myeloid leukemia
via Google News
The Latest on: Acute myeloid leukemia
- New drug gives Leukemia patients hope on April 17, 2019 at 9:16 am
"She's not lying when she said she was at death's door." Shuey was diagnosed with acute myeloid leukemia (AML) - an aggressive type of cancer that can affect every organ of the body. It's ... […]
- Rapidly expanding treatment options improving survival in acute myeloid leukemia on April 17, 2019 at 7:52 am
ORLANDO — Treatment options in acute myeloid leukemia are changing rapidly and improving OS of young and elderly patients, according to a presenter at Community Oncology Conference. The changes in ... […]
- Leukemia Protein Atlas Holds Power to Accelerate Precision Medicine on April 17, 2019 at 7:15 am
... improve survival rates and aid scientific research for one of the most severe forms of leukemia— acute myelogenous leukemia (AML)—researchers at The University of Texas at San Antonio (UTSA) and ... […]
- Online atlas created to identify, classify protein signatures present at AML diagnosis on April 17, 2019 at 5:15 am
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at The University of Texas at ... […]
- The Leukemia Atlas: researchers unveil proteins that signal disease on April 17, 2019 at 1:48 am
Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at The University of Texas ... […]
- Computational researchers and oncologists develop protein cancer atlas to accelerate personalized medicine for leukemia patients on April 17, 2019 at 1:08 am
(April 17, 2019) -- Only about one in four people diagnosed with acute myelogenous leukemia (AML) survive five years after the initial diagnosis. To improve that survival rate, researchers at UTSA and ... […]
- Ivosidenib Holds Greatest Benefit for Older Patients With IDH1-Mutant AML on April 16, 2019 at 11:03 am
Ivosidenib (Tibsovo) is changing the treatment landscape for adult patients with relapsed or refractory acute myeloid leukemia (AML) with an IDH1 mutation. The FDA approved ivosidenib in July 2018 to ... […]
- Quizartinib Poised to Expand FLT3 Inhibition Options in AML on April 16, 2019 at 7:05 am
Quizartinib, a novel small molecule FLT3 inhibitor, is moving through the pipeline of new drugs under development for patients with FLT3-mutated acute myeloid leukemia (AML), part of a menu of ... […]
- Copay Assistance From The Assistance Fund Now Available for Eligible People Living With Acute Myeloid Leukemia on April 16, 2019 at 7:00 am
ORLANDO, Fla., April 16, 2019 /PRNewswire/ -- The Assistance Fund, an independent charitable patient assistance foundation that helps patients and families facing high medical out-of-pocket costs ... […]
- Oklahoma Man Reflects On Beating Leukemia After Experimental Trial on April 11, 2019 at 8:08 pm
In 1968, that's how Clint Kindell dealt with the grave news about his older brother Greg, who was diagnosed with Acute Myeloid Leukemia or AML. He was just 17 years old. "It was absolutely a death ... […]
via Bing News